Home > List All Publishers > CHI Insight Pharma Reports

CHI Insight Pharma Reports

CHA Advances Reports are a service of Cambridge Healthtech Advisors. Advances Reports are written by experts who collaborate with CHA to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.

Advances Reports offer:

Current information and analysis of R&D technologies, therapeutic markets, and critical business issues.

Analysis of the probability of success for various applications of each technology.

Interviews with key personnel in companies at the forefront of technological advances.

Competitive insight on the business strategies and activities of key companies.

List of reports from CHI Insight Pharma Reports

2015: Strategic Considerations for the U.S. Pharmaceutical Industry 2/1/2004 \| published by: CHI Insight Pharma Reports ... insightful and creative business strategies to navigate through the challenges, capitalize on the opportunities, and adapt to change. This report offers a thorough analysis of current trends and issues that are challenging high-level decision making, ... \| more... Search inside this report	$3,750.00
A New Paradigm for Clinical Development: The Clinical Trial in 2015 12/1/2005 \| published by: CHI Insight Pharma Reports ... a conceptual, technical and logistical point of view. The current clinical evaluation process is fraught with inefficiencies, resulting in numerous compound failures and exploding development costs. Until recently, the industry has reacted to the clinical ... \| more...	$2,750.00
Adaptive Clinical Trials: Innovations in Trial Design, Management, and Analysis 9/1/2007 \| published by: CHI Insight Pharma Reports ... report is a comprehensive assessment of the benefits, challenges, and accumulated industry experience with regard to adaptive clinical trials. It includes: A critique of the structural, conceptual, and ethical issues inherent in the traditional clinical ... \| more...	$2,995.00
Advances in Lead Optimization Accelerating Drug Discovery and Development 2/1/2003 \| published by: CHI Insight Pharma Reports ... cost of drug discovery and development, a major shift is occurring in how pharmaceutical companies evaluate drug leads. Whereas researchers used to begin by looking at affinity and potency, a genomics/informatics-based research culture is growing ... \| more... Search inside this report	$1,500.00
Animal Models for Therapeutic Strategies 3/1/2010 \| published by: CHI Insight Pharma Reports ... Case studies of the use of established animal models in developing novel therapeutic strategies Emerging animal models for use in drug discovery and the development of new therapeutic strategies Development of animal models that are ... \| more...	$2,995.00
Antibiotic R&D: Resolving the Paradox between Unmet Medical Need and Commercial Incentive 7/1/2008 \| published by: CHI Insight Pharma Reports ... combating the emergence and spread of novel, drug-resistant bacterial strains. This new report offers in-depth analysis of: Factors driving the field forward and opportunities for large and small pharma The key scientific challenges to antibiotic ... \| more...	$2,995.00
Antiviral Therapeutics: Pipelines and Competitive Dynamics 7/1/2006 \| published by: CHI Insight Pharma Reports ... The ability of viruses to develop resistance against drugs, coupled with sub-optimal treatment outcomes as a result of failure of patients to comply with the full course of therapy, will continue to provide the commercial ... \| more...	$2,750.00
Approaches to Reducing Phase II Attrition 5/1/2009 \| published by: CHI Insight Pharma Reports ... improve success rates of therapeutic candidates in clinical development The use of translational medicine studies and early clinical trial protocols designed to reduce Phase II attrition Survey results and expert interviews on efforts to improve ... \| more...	$2,995.00
Autoimmune Diseases: Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis 6/1/2011 \| published by: CHI Insight Pharma Reports ... targets are actively being investigated and what new targets are coming forward? Who has candidates in active Phase III and Phase II clinical trials? What does the overall target activity map, from launched drug to ... \| more...	$795.00
Backup Compound Strategies: Best Practices for Reducing Phase II Risk 9/1/2007 \| published by: CHI Insight Pharma Reports ... that there is no surer way to minimize Phase II risk than a well thought-out backup plan. This report drives home real world experiences and best practices in backup compound strategies with: Case studies of ... \| more...	$2,995.00
Backup Compound Strategies: Commercial and Tactical Considerations - Overview 4/1/2012 \| published by: CHI Insight Pharma Reports ... significant investments. Planning optimal backup compound strategies is often difficult. This Insight Pharma Report: Describes how companies are addressing strategic and tactical issues concerning backup compounds and predicts how they are likely to do so ... \| more...	$9,950.00
Biochemical Pathway and Systems Analysis for Target Identification and Validation 4/1/2002 \| published by: CHI Insight Pharma Reports ... numerous drug discovery researchers and is central to the strategy of many biopharmaceutical and genomic companies. Biochemical Pathway and Systems Analysis for Target Identification and Validation examines various types of biochemical pathways, including metabolic and ... \| more... Search inside this report	$1,500.00
Bioinformatics and Computational Biology: Bottlenecks and Options 6/1/2009 \| published by: CHI Insight Pharma Reports ... we once associated only with semiconductor devices. This report explores the interlocking challenges facing instrumentation advances, computational demands and our evolving systems biology knowledge. Key challenges presented in this report include: Instrumentation capable of generating ... \| more...	$2,995.00
Biomarker Partnering Terms and Agreements, 3rd Edition 2/1/2012 \| published by: CHI Insight Pharma Reports ... in biomarker partnering deals Deal terms analaysis Average biomarker deal values Biomarker partnering agreement structure Biomarker partnering contract documents Top biomarker deals by value Most active biomarker dealmakers The Biomarker Partnering Terms and Agreements report ... \| more...	$2,695.00
Biomarker SOPs: Getting Optimum Value from Your Biomarker Programs 1/1/2007 \| published by: CHI Insight Pharma Reports ... procedures (SOPs) for planning, implementing, and employing biomarkers remain a work in progress, continually evolving as still-scarce outcomes data from biomarker-driven programs becomes available. Based on extensive interviews with senior managers and thought leaders, Biomarker ... \| more...	$3,000.00
Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D 3/1/2005 \| published by: CHI Insight Pharma Reports ... to the clinic. Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D evaluates the following technologies, strategies, and issues in biomarker research: Technologies to discover and screen biomarkers, particularly with regard to their ... \| more... Search inside this report	$4,200.00
Biomedical Imaging: From Drug Target Discovery to Medical Diagnostics 12/1/2008 \| published by: CHI Insight Pharma Reports ... both relevant to pharmacology and drug development. This report: Reviews the current and emerging technologies of bioimaging Focuses on the use of molecular imaging in drug discovery and development from cell-based screening to clinical trials ... \| more...	$2,995.00
Blood-Brain Barrier: Bridging Options for Drug Discovery and Development 5/1/2008 \| published by: CHI Insight Pharma Reports ... results from a Blood-Brain Barrier Survey, responded to by a range of companies involved in CNS research and drug discovery/development CNS diseases are a major focus of the pharmaceutical industry, with CNS drugs representing some ... \| more...	$2,500.00
Cancer Biomarkers: Adoption Is Driving Growth 7/1/2008 \| published by: CHI Insight Pharma Reports ... cancer biomarker programs integrating established “standards of care” for cancer diagnosis and treatment Product opportunities for improved screening and early detection, to provide better guidance on therapy, for understanding cancer staging, response to treatment, and ... \| more...	$2,995.00
Cancer Diagnostics: Technology and Business Trends 9/1/2005 \| published by: CHI Insight Pharma Reports ... pharmacodiagnostic cancer tests. The field of theranostics—the development of tests to predict response to therapy or to identify the optimal therapy for a patient: DakoCytomation EGFR PharmDx test. Immunophenotyping of leukemia and lymphoma. Potential opportunities ... \| more...	$2,750.00
Cancer Genomics: Revolutionizing Treatment and Reshaping Markets through Targeted Therapies 8/1/2003 \| published by: CHI Insight Pharma Reports ... strongly by genomics and related technologies than any other indication area. Cancer arises from genetic changes in cells and hence, the availability of tools to better understand exactly how this occurs is revolutionizing the field. ... \| more... Search inside this report	$2,150.00
Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics 11/1/2006 \| published by: CHI Insight Pharma Reports ... approaches. Foremost among these are therapies that enhance the ability of the body's own immune system to fight and destroy abnormal cancer cells. Anticancer vaccines and immune modulators, working in concert and as monotherapy, stole ... \| more...	$2,750.00
Cancer Vaccines Market Study 1/1/2012 \| published by: CHI Insight Pharma Reports ... cancer vaccines, which was designed to focus on standardized immunogenic vaccines vs. autologous cell therapies or passive immunotherapies. Included in this 20 page Industry Market Study is Expert Interviews, Market Data, Analysis and Survey Results. \| more...	$495.00
Cardiotoxicity: Issues, Technologies, and Solutions for the Future 5/1/2008 \| published by: CHI Insight Pharma Reports ... 50 commercial entities that offer cardiotoxicity screening products/services The history and status quo of the current regulatory environment pertinent to drug-induced proarrhythmia Methods for assessing the potential for drug-induced cardiotoxicity, with a primary focus on ... \| more...	$2,995.00
Cardiovascular Diagnostics: Key Developments in Technologies and Markets 5/1/2005 \| published by: CHI Insight Pharma Reports ... to be an enormous medical and cost burden on the health care system. As the rapidly aging population drives an increase in the incidence and prevalence of heart disease, the need for early detection and ... \| more... Search inside this report	$4,200.00

< prev 1 2 3 4 5 6 next >